A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality

被引:17
作者
Huang, Xuelin [1 ]
Li, Yisheng [1 ]
Song, Juhee [1 ]
Berry, Donald A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, 1400 Pressler St,Unit 1411, Houston, TX 77230 USA
关键词
adjuvant treatments; approximate Bayesian computation; Bayesian simulation; beyond stage-shift; breast cancer; cancer screening; mammography; AGE; 40; YEARS; DEATH RATES; FOLLOW-UP; WOMEN; MAMMOGRAPHY; TRIAL;
D O I
10.1177/0272989X17714473
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. The important but complicated research questions regarding the optimization of mammography screening for the detection of breast cancer are unable to be answered through any single trial or a simple meta-analysis of related trials. The Cancer Intervention and Surveillance Network (CISNET) breast groups provide answers using complex statistical models to simulate population dynamics. Among them, the MD Anderson Cancer Center (Model M) takes a unique approach by not making any assumptions on the natural history of breast cancer, such as the distribution of the indolent time before detection, but simulating only the observable part of a woman's disease and life. Methods. The simulations start with 4 million women in the age distribution found in the year 1975, and follow them over several years. Input parameters are used to describe their breast cancer incidence rates, treatment ecacy, and survival. With these parameters, each woman's history of breast cancer diagnosis, treatment, and survival are generated and recorded each year. Research questions can then be answered by comparing the outcomes of interest, such as mortality rates, quality-adjusted life years, number of false positives, differences between hypothetical scenarios, such as different combinations of screening and treatment strategies. We use our model to estimate the relative contributions of screening and treatments on the mortality reduction in the United States, for both overall and different molecular (ER, HER2) subtypes of breast cancer. Results. We estimate and compare the benefits (life-years gained) and harm (false-positives, over-diagnoses) of mammography screening strategies with different frequencies (annual, biennial, triennial, mixed) and different starting (40 and 50 years) and end ages (70 and 80 years). Conclusions. We will extend our model in future studies to account for local, regional, and distant disease recurrences.
引用
收藏
页码:78S / 88S
页数:11
相关论文
共 35 条
[1]  
Alagoz O, 2018, MED DECIS MAKING, V38, P3
[2]   The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update [J].
Alagoz, Oguzhan ;
Ergun, Mehmet Ali ;
Cevik, Mucahit ;
Sprague, Brian L. ;
Fryback, Dennis G. ;
Gangnon, Ronald E. ;
Hampton, John M. ;
Stout, Natasha K. ;
Trentham-Dietz, Amy .
MEDICAL DECISION MAKING, 2018, 38 :99S-111S
[3]  
[Anonymous], 2002, Cancer Staging Manual, V6th
[4]  
[Anonymous], 1996, Tools for Statistical Inference
[5]  
[Anonymous], 1988, PERIODIC SCREENING B
[6]  
[Anonymous], SEER STAT DAT INC SE
[7]  
Berry D.A., 1996, Bayesian Biostatistics
[8]   Effect of screening and adjuvant therapy on mortality from breast cancer [J].
Berry, DA ;
Cronin, KA ;
Plevritis, SK ;
Fryback, DG ;
Clarke, L ;
Zelen, M ;
Mandelblatt, JS ;
Yakovlev, AY ;
Habbema, JDF ;
Feuer, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792
[9]  
Berry DA., 1996, STAT BAYESIAN PERSPE
[10]  
Berry Donald A, 2006, J Natl Cancer Inst Monogr, P30, DOI 10.1093/jncimonographs/lgj006